EarningsNYSE:HPQ
HP shares slide 9.0%, wiping out $2.5 billion after PC shipments sink 16%
PALO ALTO, California, August 26, 2026, 17:03 — HP Inc's stock dropped 9.0%, erasing $2.5 billion in market value, after the company reported a…
Market intelligence
Latest market intelligence
Fast, evidence-led coverage of the companies and events moving global markets.
All coverage
More market stories
HP Inc. · NYSE:HPQ
Price/mix beat, unit-demand warning
Market snapshot: August 26, 2026, 17:02 EDT
After hours · −9.03%
After-hours price
$27.77
−$2.75 from the $30.52 close
Value erased
≈$2.5B
Implied from the closing market cap
Revenue surprise
+8.6%
$15.68B vs $14.44B consensus
Adjusted EPS surprise
+25.8%
$0.83 vs $0.66 consensus
Why the stock reversed
PC units−16%
PC revenue+18%
Print revenue−2%
The divergence matters. A simple revenue-to-units calculation implies roughly 40% higher Personal Systems revenue per unit. Pricing and premium mix did the heavy lifting while underlying unit demand contracted.
Session reversal
Regular close: 16:00:02 EDT. After-hours quote: 17:02:21 EDT.
Quarter and guidance
| Metric | Result / guide | Reference |
|---|---|---|
| Q3 revenue | $15.68B | $14.44B est. |
| Q3 adjusted EPS | $0.83 | $0.66 est. |
| Q3 net income | $661M | $763M year ago |
| FY adjusted EPS | $3.19–$3.29 | $2.90–$3.10 prior |
| FY free cash flow | $3.0–$3.2B | $2.8–$3.0B prior |
| Q4 adjusted EPS | $0.69–$0.79 | $0.67 consensus |
Business mix and earnings quality
Printing’s 2% decline is important because the segment has carried far higher margins. In fiscal Q2, Personal Systems margin was 5.2%; Printing margin was 18.3%.
Tariff refunds added $0.11 to Q3 EPS and are expected to add $0.19 for the year. The annual benefit equals 5.9% of the new guidance midpoint.
Valuation and peer context
| Company | Aug. 26 close | Session move | Market cap | P/E |
|---|---|---|---|---|
| HP (HPQ) | $30.52 | +3.39% | $28.23B | 11.3× |
| Dell (DELL) | $463.82 | +2.77% | $304.27B | 37.0× |
| Apple (AAPL) | $313.45 | +1.16% | $4.61T | 36.0× |
| Logitech (LOGI) | $100.19 | +1.56% | $14.53B | 18.4× |
HP’s lower multiple prices in a structurally weaker mix and limited unit growth. At the $27.77 after-hours price, the $23.41 one-year analyst target implied 15.7% downside. The $3.1 billion free-cash-flow midpoint equaled roughly 12% of implied after-hours equity value.
Peer prices and valuation snapshot: August 26, 2026, approximately 16:45–16:50 EDT. HP after-hours valuation is an estimate using the closing share count.
Signals to watch
- PC unit guidance and price elasticity after the 16% shipment decline.
- Memory-cost timing versus price increases.
- Premium and AI-PC mix after the revenue-per-unit jump.
- Printing revenue and supplies trajectory.
- Cash conversion behind the $3.0–$3.2 billion FCF guide.
Risk map
Demand: Higher prices may suppress replacement units.
Margins: Memory inflation may arrive before pricing catches up.
Mix: PC growth has lower margins than Printing.
Quality: Tariff refunds are nonrecurring.
Sentiment: The analyst target remains below the traded price.
Immediate catalyst
HP fiscal Q3 earnings call — August 26, 2026, 17:30 EDT. The market needs a bridge from strong revenue to sustainable unit growth and margins. Guidance on memory supply, pricing, Printing and refund-adjusted earnings will set the next move.
Sources: Reuters · The Wall Street Journal · Yahoo Finance · HP investor relations
Figures are reported data or clearly marked calculations. After-hours prices can change rapidly and carry less liquidity than the regular session.
EarningsNASDAQ:OKTA
Okta Shares Surge 15.7%, Market Value Rises by $3.5 Billion on Faster Backlog Growth
SAN FRANCISCO, August 26, 2026, 16:49 EDT — Okta's stock climbed 15.7%, boosting its market capitalization by $3.5 billion as the company reported an…
NASDAQ: OKTA · Company stock move
Backlog acceleration reprices Okta
Fiscal Q2 2027 earnings · identity and access management
Market snapshot: August 26, 2026, 16:46 EDT
Financials and guidance: August 26, 2026
Financials and guidance: August 26, 2026
After-hours price
$155.47
vs. $134.42 regular close
After-hours move
+15.66%
+$21.05 per share
Implied value added
≈$3.50B
166.12M shares × $21.05
Remaining obligations
$4.858B
+17% year over year
Q2 operating scorecard
Q2 FY2026Q2 FY2027
Why the move matters
The market added almost four times the raised full-year free-cash-flow midpoint. Sustained backlog conversion is now the central valuation test.
FY2027 guidance reset
| Metric | Prior midpoint | New midpoint | Change |
|---|---|---|---|
| Revenue | $3.195B | $3.221B | +$26M |
| Adjusted operating income | $816M | $835M | +$19M |
| Adjusted EPS | $3.83 | $3.92 | +$0.09 |
| Free cash flow | $870M | $920M | +$50M |
Street positioning
| Ratings | 46 |
| Buy / Overweight / Hold | 29 / 6 / 9 |
| Underweight / Sell | 2 / 0 |
| Average target | $147.18 · 5.3% below |
| Median target | $161 · 3.6% upside |
| Target range | $75–$180 |
Analyst recommendations and targets as of the August 26, 2026 close.
Near-term signals
Revenue +11%Subscription +12%RPO +17%cRPO +14%FCF +40%- Q3 revenue midpoint: $815M, about 0.9% above consensus.
- Q3 EPS midpoint: $0.93, one cent below consensus.
- Regular volume: about 5.9M, roughly 1.6× the 65-day average.
- Identity Governance and machine-identity demand led management’s product message.
Risk monitor
- Valuation: the after-hours price exceeded the pre-report average analyst target.
- Cash cadence: Q3 FCF margin guidance of 21%–23% trails Q2’s 28%.
- Execution: enterprise renewals must sustain current-RPO growth.
- Operating risk: competition or a security incident could impair demand.
- Management’s earnings call began at 17:00 EDT on August 26.
Artificial IntelligenceNYSE:CRM
Salesforce Gains 12.7%, Market Value Rises by $22.8 Billion as AI ARR Approaches $4 Billion
Salesforce, Inc. stock surged 12.73% in postmarket trading on Wednesday. The gain came after fiscal second-quarter results reinforced the company's AI-driven growth outlook.
NYSE: CRM · Company stock move
AI contract momentum, not the headline EPS, drove the re-rating
Salesforce added an implied $22.8 billion of equity value after hours. The cleaner operating signal was $3.37 adjusted EPS excluding investment gains, while Agentforce and Data 360 ARR approached $3.9 billion.
After-hours price
$231.80
+$26.18 · +12.73%
August 26, 2026 · 16:37:36 EDT
Regular close: $205.62
Regular close: $205.62
Implied market value
$201.9B
+$22.8B after hours
Calculated from the $179.1B closing value.
AI + data ARR
$3.9B
+210%+ YoY
Agentforce and Data 360 recurring revenue.
Q2 revenue
$11.35B
+11% YoY
$11.33B consensus; 0.2% beat.
Current RPO
$33.5B
≈+14% YoY
Slightly above the $33.4B expectation.
What changed in guidance
PriorNew revenueNew EPS
Market-value bridge
The equity-value gain was about 114 times the $200 million increase in the fiscal-year revenue-guidance midpoint.
Quarter and outlook
| Metric | Reported / guided | Benchmark | Signal |
|---|---|---|---|
| Q2 revenue | $11.35B | $11.33B consensus | Small beat |
| Adjusted EPS | $5.90 | $3.27 consensus | Investment gains amplified it |
| EPS ex investment gains | $3.37 | $3.27 consensus | 3.1% beat |
| Q3 revenue | $11.42B–$11.50B | New guidance | Steady double-digit scale |
| Q3 adjusted EPS | $3.42–$3.44 | New guidance | Operating leverage |
| FY27 revenue | $46.1B–$46.4B | Prior $45.9B–$46.2B | Midpoint +$200M |
| FY27 adjusted EPS | $16.67–$16.71 | Prior $14.06–$14.12 | Midpoint +18.5% |
Valuation after the jump
| Implied market cap / trailing revenue | 4.7× |
| Implied market cap / FY27 revenue midpoint | 4.4× |
| Implied P/E using trailing EPS | 26.8× |
| Levered free-cash-flow yield | 8.2% |
| Average analyst target | $243.98 · 5.3% upside |
| Citizens target | $315 · 35.9% upside |
| 52-week range | $146.32–$269.11 |
| Estimated YTD after the move | about −12% |
Valuation ratios use the $231.80 after-hours price and latest trailing figures available at 16:37 EDT.
Peer tape at the regular close
| Company | Ticker | Close | Move |
|---|---|---|---|
| Salesforce | CRM | $205.62 | −0.03% regular / +12.73% AH |
| ServiceNow | NOW | $125.80 | −0.94% |
| Adobe | ADBE | $273.47 | −0.16% |
| Snowflake | SNOW | $315.37 | −0.52% |
Peer prices are the August 26 regular-session closes; Salesforce’s earnings move occurred afterward.
Investor interpretation
The positive read: AI and data ARR nearing $4 billion gives investors a measurable commercial bridge. The strongest net-new annual order growth in four years suggests the signal reaches beyond pilot activity.
The test: The $22.8 billion revaluation needs organic cRPO growth and repeatable Agentforce bookings. A $200 million revenue-guide lift alone does not explain it.
Risks: Strategic-investment gains may reverse. Informatica and pending acquisitions blur organic growth. Customer deployments can remain slow where data is fragmented.
Next catalyst: the 17:00 EDT earnings call. Watch Agentforce bookings, organic growth, free cash flow, acquisition assumptions and any change to capital returns.
CybersecurityNASDAQ:CRWD
CrowdStrike shares soar 10.9%, market value up $21 billion on faster ARR growth
AUSTIN, Texas, August 26, 2026, 16:40 EDT — CrowdStrike stock climbed 10.9%, increasing its market capitalisation by $21 billion after the company reported an…
NASDAQ: CRWD · Company · Stock move
Record ARR growth resets the earnings bar
As of August 26, 2026, 16:40 EDT. After-hours quote; financial data covers fiscal Q2 ended July 31, 2026.
After-hours price
$209.77
Regular close: $189.18
After-hours move
+10.88%
+$20.59 per share
Implied value added
≈$21.0B
Using 1.02B shares outstanding
Net new ARR
$332.8M
Record; +51% year over year
Quarterly acceleration
What moved the stock
Revenue$1.471B · +26%
Subscription revenue$1.400B · +27%
Ending ARR$5.84B · +25%
Falcon Flex ARR>$2.29B · +101%
Free cash flow$377.4M · +33%
Regular volume12.2M · 115% avg.
Guidance: old bar versus new bar
| Fiscal 2027 | Previous | Current |
|---|---|---|
| Revenue midpoint | $5.937B | $6.001B |
| Ending ARR midpoint | $6.544B | $6.607B |
| Net new ARR growth | 27.7% | 34.0% |
| Adjusted EPS | $1.21–$1.24 | $1.25–$1.26 |
Analyst expectations before the print
ConsensusOverweight · 54 ratings
Buy / Overweight35 / 5
Hold / Underweight / Sell12 / 2 / 0
Average target$214.43 · +2.2%
Median target$228.50 · +8.9%
Target range$103–$256
Valuation and financial signal
FY27 adjusted EPS midpoint$1.255
Price / guided adjusted EPS≈167×
Value gain / quarterly FCF≈56×
Falcon Flex share of ARR≈39%
Price versus median target
The after-hours price already captures most of the pre-results median target.
Risks and next checks
- Execution: record pipeline must convert into the raised $6.607B ARR midpoint.
- Valuation: a 167× guided adjusted-EPS multiple magnifies small forecast misses.
- Accounting gap: $399.0M of stock compensation helped separate a $33.2M GAAP loss from $371.6M non-GAAP operating income.
- Product risk: outages, faulty updates or weaker renewals can slow platform expansion.
- Next dated catalyst: investor briefing at Fal.Con on September 2, 2026.
Sources: CrowdStrike fiscal Q2 2027 release; MarketWatch delayed after-hours quote and FactSet analyst estimates. After-hours trading can be less liquid and more volatile than the regular session.
Artificial IntelligenceNASDAQ:NVDA
Nvidia Shares Drop 1.8% Following $96.2 Billion Quarterly Revenue, With AI Commitments Now at $366 Billion
SANTA CLARA, California, August 26, 2026, 16:30 EDT — Nvidia stock declined by 1.8% after reporting quarterly revenue of $96.2 billion, as the company’s…
NVIDIA · NASDAQ:NVDA · Q2 FY2027
Revenue beat, balance-sheet test
Market data: Aug. 26, 2026, 16:30 EDT
Financials: quarter ended July 26, 2026
Financials: quarter ended July 26, 2026
After hours
$205.92 · -1.78%
Close $209.66 · about $90B value erased
Q2 revenue
$96.22B
+106% YoY · +4.2% vs FactSet consensus
Q3 outlook
$108.0B
+3.6% vs $104.2B consensus · ±2% range
Commitments + guarantees
$474.5B
8.4× cash and marketable debt securities
Revenue acceleration
Q2 Data Center revenue was $89.0B, or 92.5% of total sales.
Investor bridge
| Measure | Value | Signal |
|---|---|---|
| Adjusted EPS | $2.22 | +6.2% vs est. |
| Q2 gross margin | 75.0% | Flat QoQ |
| Q3 gross margin | 74.0% | -1.0 pt |
| Free cash flow | $21.34B | -56% QoQ |
| DSO | 60 days | +15 days |
Commitment stack
Supply and capacity · $279B
Other contractual commitments · $87B
Contingent guarantees · $108.5B
Supply commitments rose $160B, or 134%, in one quarter. The guarantee total includes $105B for the Ohio site and $3.5B for AI-cloud leases.
Operating signals
| Metric | Q2 FY27 | Sequential | Why it matters |
|---|---|---|---|
| Data Center | $89.0B | +18% | Core demand remains strong |
| ACIE | $40.3B | +25% | Faster than hyperscale |
| Receivables | $63.1B | DSO 45→60 | Cash conversion slowed |
| Inventory | $31.6B | +22% | Rubin launch build |
| Operating cash flow | $24.1B | -52% | Working capital and taxes |
What changes the thesis
Bull: $108B revenue converts to cashBull: ACIE sustains 25% QoQ growthBear: margin falls below 73.5%Bear: DSO extends againBear: customer guarantees activate
Commitments are future obligations, not immediate debt. Guarantees are contingent. The valuation test is whether Nvidia's revenue and free cash flow scale faster than supply, lease and customer-support exposure.
Artificial IntelligenceStock Market
Volato Shares Jump 62% After $500 Million AI Merger Surpasses $13 Million Market Capitalization
ATLANTA, August 26, 2026, 15:48 – Volato surged 62% following an announcement of a $500 million artificial intelligence merger, vastly outstripping the company's $13…
Volato Group · NYSE American:SOAR
A $500 million merger meets a $13 million stock
AI-infrastructure transaction dashboard for U.S. investors
26 Aug 2026 · 15:48 EDT
Share price
~$0.25
▲ 61.83% · +$0.097
Intraday, 15:48 EDT
Trading volume
732.24m
46.0× average
Average: 15.93m shares
Value added
~$5.2m
$0.097 × 53.63m shares
Current market cap
$13.16m
2.6% of target valuation
Valuation gap
Transaction currencyConvertible preferred stock
Conversion ratioNot disclosed
Post-deal ownership splitNot disclosed
Power-to-compute buildout
Available today154 MW
Planned total480 MW
Expansion factor3.1×
Intended workloadsGPU compute · training · inference · HPC
CampusPowered industrial site in Ohio
Volato financial base
| Measure | Latest | Read-through |
|---|---|---|
| Q2 revenue | $0.965m | Small operating base |
| Q2 operating loss | $2.52m | Loss exceeds revenue |
| Cash | $8.44m | 30 Jun 2026 |
| Working capital | ~$0.9m | Limited cushion |
| H1 financing cash | $7.0m | Mostly equity issuance |
| Employees | 13 | Major operating pivot |
Share-supply signal
2026 shares issued through June29.7m
Shares outstanding53.63m
Issued / current shares55%
52-week range$0.10–$3.87
Tracked analyst consensusNone reliably available
Prior equity use makes the new preferred-stock conversion terms the central per-share variable.
Deal path and risk gates
1 · SignedDefinitive agreement announced August 26
2 · Closing conditionsThird-party consents and other conditions remain
3 · Exchange reviewNYSE American must approve the change of control
4 · Conversion voteShareholders later vote on preferred-stock conversion
Capital riskData-center expansion requires substantial funding
Disclosure riskNo target financials or customer contracts published
Dilution riskConversion ratio and ownership split remain unknown
Execution riskVolato must integrate a capital-intensive new business
Sources: Volato Group merger release and Q2 2026 Form 10-Q; Google Finance market data. Market figures are intraday and timestamped above. Ratios are calculated from disclosed values and rounded.
BiotechnologyNASDAQ:GENB
Generate Biomedicines Stock Slides 20% as 103 Million Shares Clear Lock-Up
Generate Biomedicines Inc. shares fell 20.3% to $16.25 at 15:06 EDT. The decline erased about $530 million of quoted equity value.
NASDAQ: GENB · Investor dashboard
Lock-up supply resets the valuation debate
A 103.14 million-share resale block became eligible as Generate Biomedicines returned near its $16 IPO price. The September 8 GB-0895 data now become the next fundamental test.
Market snapshot
Aug. 26, 2026 · 15:06 EDT
Aug. 26, 2026 · 15:06 EDT
STOCK MOVELOCK-UP
Share price
$16.25
Aug. 26, 15:06 EDT
Session move
−20.3%
−$4.13 per share
Volume
3.06M
3.4× 3-month average
Market value
$2.09B
At 15:06 EDT
Information gain: the day’s $4.13 decline erased roughly $530 million of quoted equity value. The unlocked block itself was worth about $1.68 billion at $16.25.
Potentially sale-eligible share pool
SEC share count: 128.27M at June 30, 2026. Eligibility does not prove actual selling.
Price path: rally, reversal, reset
Aug. 21 close
$16.12
Aug. 24 close
$17.72
Aug. 25 close
$20.38
Aug. 26, 15:06
$16.25
GENB rose 26.4% from Aug. 21 through Aug. 25, then gave back nearly the entire advance. It remained 1.6% above the $16 IPO price at 15:06 EDT on Aug. 26.
Balance-sheet and operating signals
| Metric | Latest | Investor read |
|---|---|---|
| Cash + securities | $457.4M | 21.9% of market cap |
| H1 operating cash use | $138.3M | Runway into H1 2028 |
| Q2 collaboration revenue | $6.3M | −37.7% year over year |
| Q2 net loss | $67.3M | Widened from $56.7M |
| Q2 GB-0895 external R&D | $20.5M | +54.3% year over year |
Catalyst clock
Feb. 27IPO priced at $16; 25M shares sold for $400M gross.
Aug. 25 closeRestrictions lift on 103.14M shares, subject to securities laws.
Sept. 8GB-0895 Phase 1b COPD safety, PK and PD poster at ERS 2026.
H1 2028Management’s current cash-runway horizon and planned Phase 3 enrollment window.
What changes next: ownership supply drove this session. September data can shift the focus back to GB-0895’s pharmacology and the twice-yearly dosing case.
Analyst expectations
Average target
$25.60
Six analysts
Target range
$22–$30
S&P Global poll
As of Aug. 26, 2026. Morgan Stanley reiterated Buy with a $22 target on Aug. 17; Piper Sandler reiterated Buy with a $24 target on Aug. 7.
Investor frame
Bull case: little actual lock-up selling would make the 20% drop look like a temporary supply discount. Positive COPD data could strengthen the six-month dosing proposition ahead of larger severe-asthma readouts.
Risk case: sustained insider or venture-holder sales could cap rebounds. Weak September pharmacology, faster cash use, or Phase 3 delays would raise financing and dilution risk before commercialization.
NASDAQ:METANYSE:SNAP
Snap shares lose nearly 8% as investors react to Pennsylvania youth-safety lawsuit and Meta settlement
WARSAW, August 26, 2026, 21:10 CEST — Shares in Snap Inc. dropped 7.94% to $5.45 on Wednesday afternoon as a youth-safety lawsuit in Pennsylvania…
Snap Inc. NYSE: SNAP
Event-driven investor dashboard
Regular session · delayed feed
Pennsylvania teen-safety lawsuit
Snap slides 7.9% as a new state case sharpens the legal overhang
Pennsylvania sued Snap under its consumer-protection law, alleging deceptive safety and age-rating claims and an addictive, high-risk design for minors. These are allegations, not findings; the complaint specifies no dollar liability.
$5.45
−$0.47 / −7.94%
Prior close $5.92
Open $5.97
Day $5.33–$6.01
52-week $3.81–$9.28
Market snapshot: Aug. 26, 2026, 2:47:31 p.m. EDT · latest trade in delayed consolidated feed · retrieval 3:02:58 p.m. EDT
Volume
52.0M
1.24× 3-month average of ~41.93M · Aug. 26, 2:47 p.m. EDT
Market value
~$9.1B
Intraday vendor estimate · Aug. 26, 2:47 p.m. EDT
From 52-week high
−41%
Derived from $5.45 and $9.28 · Aug. 26 snapshot
From 52-week low
+43%
Derived from $5.45 and $3.81 · Aug. 26 snapshot
Tape check
All values: Aug. 26, 2026, about 2:47 p.m. EDT · delayedWhere the latest trade sits
Peer tape
SnapNYSE: SNAP · P/E N/M
$5.45
−7.94%
Meta PlatformsNASDAQ: META · TTM P/E ~21.9×
$580.65
+1.86%
PinterestNYSE: PINS · TTM P/E ~68.9×
$23.41
−1.06%
SNAP underperformed META by 9.80 percentage points and PINS by 6.88 points at the same snapshot. That comparison supports a stock-specific repricing; it does not prove the lawsuit caused every part of the move.
Reuters reported that Meta separately agreed to pay up to $18 billion and make youth-safety product changes. Snap is not a party to that settlement, but its scale supplies a same-day industry benchmark for legal and product-remedy risk.
Catalyst: what Pennsylvania filed
Public redacted complaint dated Aug. 25, 2026Commonwealth v. Snap Inc.
Philadelphia Court of Common Pleas · Pennsylvania Unfair Trade Practices and Consumer Protection Law (UTPCPL)
- The state alleges Snap understated mature content to secure age ratings suitable for users 13 and older.
- It challenges features including infinite scroll, autoplay, notifications, Snapstreaks, friend discovery, location sharing and ephemeral messages as deceptive or unfair for minors.
- The requested relief includes declarations, temporary and permanent injunctions, civil penalties, costs, fees and other equitable relief.
- No dollar damages amount is stated in the complaint’s prayer for relief.
Snap said the allegations “fundamentally misrepresent our platform and our approach to teen safety,” and said it remains focused on strengthening safeguards. The case is at the allegation stage.
Why the market can care before damages are known
The near-term issue is remedy uncertainty. An injunction could matter through product design, marketing, compliance cost or engagement—not only through a cash penalty.
ComplaintUTPCPL claims filed Aug. 25
Possible remedyOnly if the state prevails or parties settle
Product effectDesign, ratings, marketing or youth safeguards
Financial channelEngagement, ad inventory, cost or cash outflow
Risk transmission, not a forecast. Snap’s Aug. 4 10-Q—filed before this Pennsylvania case—already said youth-harm litigation outcomes were uncertain and that it could not estimate a reasonably possible loss range for those matters.
Fundamental counterweight
Q2 2026 · three months ended June 30, 2026 · company-reportedQ2 scorecard
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | $1.599B | $1.345B | +19% |
| Advertising revenue | $1.283B | $1.174B | +9% |
| Other revenue | $316M | $171M | +85% |
| Adjusted EBITDA | $250M | $41M | +505% |
| Net loss | $(164)M | $(263)M | 38% narrower |
| Free cash flow | $121M | $24M | +407% |
| Average DAU | 493M | 469M | +5% |
| Global ARPU | $3.25 | $2.87 | +13% |
Exact reported figures were $1,598.993M revenue, $249.615M adjusted EBITDA, $(163.960)M net loss and $120.538M FCF. Adjusted EBITDA and FCF are non-GAAP measures.
Revenue is diversifying; core-market users are the watchpoint
Advertising$1.283B
Other / direct$316M
Ad mix fell from 87.3% a year earlier; subscription-led other revenue rose to 19.8%.
North America DAU−7%Q2 2026 YoY
Europe DAU−2%Q2 2026 YoY
Rest-of-world DAU+12%Q2 2026 YoY
Paying penetration<3%of 971M Q2 MAU; no exact subscriber count disclosed
Outlook, estimates and valuation
Company outlook Aug. 3 · consensus estimate update Aug. 18 · market inputs Aug. 26Company outlook
Q3 revenue$1.70–1.74BCompany guide · Aug. 3, 2026
Q3 adj. EBITDA$300–350MCompany guide · Aug. 3, 2026
FY infrastructure$1.65–1.70BRaised from $1.60–1.65B
FY stock comp.~$1.05BCompany outlook · Aug. 3
The Q3 revenue range implies roughly 12.8%–15.5% growth versus Q3 2025, derived from $1.5068B.
Street estimates
FY2026 revenue$6.69BVendor consensus · updated Aug. 18, 2026
FY2026 GAAP EPS−$0.10Vendor consensus · updated Aug. 18, 2026
Implied revenue growth~13%Derived vs. FY2025 revenue $5.931B
Company 2027 viewGAAP profitManagement expects sustained positive net income
Consensus is an aggregate, not company guidance, and can change after legal or operating developments.
Snapshot valuation
Market cap / TTM sales~1.4×$9.1B / $6.351B
EV / TTM adj. EBITDA~9.7×Approx. EV $9.9B / $1.023B
Market cap / TTM FCF~12.9×$9.1B / $706M
GAAP P/EN/MTTM GAAP net loss
Derived using the Aug. 26 intraday market value and June 30 balance sheet: $2.660B cash/securities and $3.535B debt. Snap reported 1.691B shares outstanding across all three classes as of July 30; vendors can use different share-count conventions. These are mixed-date approximations.
Analyst map
WSJ / FactSet snapshot retrieved Aug. 26, 202648 published ratings
9 Buy · 2 Overweight · 34 Hold · 0 Underweight · 3 SellAverage target$7.38+35.4% vs. $5.45
Median target$6.88+26.2% vs. $5.45
Target dispersion: $5 to $16
The $11 spread between low and high targets signals unusually broad model uncertainty. Targets are opinions, not promised outcomes.
What changes the setup
Observable checkpoints, not predictions
Legal
Relief becomes concrete
A quantified penalty, injunction request, adverse preliminary ruling or settlement term would replace today’s open-ended exposure with a more modelable cost or product constraint.
October 2026
Bellwether cases
Snap’s June 30 filing said the next two California JCCP youth-harm bellwether trials involving Snap were scheduled for October. Trial timing or resolution can reset risk expectations.
Operating proof
Q3 delivery
Revenue inside the $1.70B–$1.74B guide and adjusted EBITDA inside $300M–$350M would test whether Q2’s ad recovery and direct-revenue growth persist through the legal noise.
EnergyNASDAQ:XPON
Expion Energy Shares Surge 61% After $8.2 Million Fundraising Equates to Market Cap
Expion Energy Inc. shares surged 60.53% on Wednesday. The battery producer is funding a significant move toward Louisiana gas exploration.
NASDAQ: XPON · Event dashboard
Expion Energy’s financing-led gas pivot
Stock move, capital structure, legacy battery economics and the Louisiana exploration timetable
Market data: Aug. 26, 2026, 2:57:31 p.m. EDT
Fundamentals: quarter ended June 30, 2026
Fundamentals: quarter ended June 30, 2026
XPON price
$8.46
+60.53% · +$3.19
Aug. 26, 2:57:31 p.m. EDT
Intraday range
$6.30–$11.79
Current price sits 39% through the session range
Trading activity
32.75M
8.9× three-month average
Average volume: 3.68M shares
Equity value
$8.09M
962,000 shares outstanding; Aug. 26, 2:57 p.m. EDT
Why the financing matters
The $8.2 million initial net proceeds slightly exceed XPON’s $8.09 million market value. The balance-sheet effect is large; so is the potential share issuance.
Cash inClosed purchaseForward commitment
Proceeds waterfall
Initial gross principal$9.000M
Estimated net proceeds$8.200M
Adjusted acquisition price−$3.425M
Minimum lease allocation−$2.500M
Indicative remainder$2.275M
Remainder excludes other corporate spending and uses only the minimum lease allocation. Terms announced Aug. 24, 2026.
Potential dilution scenario
| Layer | Potential shares |
|---|---|
| Current common | 0.962M |
| Series A-1 conversion | 2.117M |
| Five-year warrants | 2.117M |
| Scenario total | 5.196M |
Existing shares would equal about 18.5% of this simple total. Preferred conversion needs shareholder approval; ownership limits, issuance caps, anti-dilution terms and cashless exercise can change the outcome.
Legacy battery business
Q2 2026 revenue$2.030M −32% YoY
Q2 gross profit$0.658M +6% YoY
Gross margin32.4% vs 20.8%
Q2 net loss$1.3M
June 30 cash$1.540M
H1 operating cash use$2.607M
Louisiana prospect
Existing leasehold~3,000 net acres
Title research~13,000 net acres
Expion net revenue interest~75%
Planned lateral length≥4,000 feet
Production/reserves disclosedNone
Acquisition and exploration terms filed Aug. 20 and announced Aug. 24, 2026.
Milestone clock
Aug. 20
Name changed to Expion Energy Inc.
Aug. 21
Private placement and $3.425M acquisition closed.
Next
Shareholder approval for Series A-1 structure; resale filing follows.
Feb. 15, 2027
Target date for mandatory lateral drilling operation, subject to exceptions.
Primary risk
Exploration
No reserves, production or project economics have been reported. A dry or uneconomic well could erase the option value.
Capital risk
Dilution
Conversion and warrants can multiply the share count. Additional preferred investment rights reach $91 million.
Coverage signal
No ratings
Google Finance showed no analyst recommendations on Aug. 26, 2026. Filings and milestones are the practical anchors.
Stock MarketTechnology
Mitsubishi Motors Shares Up 2.5% Before 2027 Pajero Launch
Mitsubishi Motors is set to debut the 2027 Pajero on September 2. The flagship SUV makes a comeback to international markets after a five-year…
Product catalyst · TYO:7211
2027 Mitsubishi Pajero
Flagship SUV return meets a low-margin growth plan.
Market data: August 26, 2026, 15:30 JST · Dashboard: August 27, 2026, 03:42 JST
Close
¥374.70
▲ 2.52%
Tokyo close, Aug. 26
Session volume
8.57M
shares traded
Market value
¥501.6B
approximate; 1.34B shares
Analyst target
¥372.83
0.5% below the close
Wednesday's price action
Open¥364.20
Low¥362.00
High / close¥374.70
Equity-value gain≈¥12.3B
Equity-value change uses the ¥9.20 share gain and 1.34 billion shares outstanding.
Fiscal 2026 operating frame
Retail volume857,000 · +8%
Net sales¥3.26T · +13%
Operating profit¥90B · +19%
Operating margin2.8% vs. 2.6%
Sensitivity: 10 basis points of margin on ¥3.26 trillion equals ¥3.26 billion, or 3.6% of guided operating profit.
Pajero commercial signal
| Signal | Verified measure |
|---|---|
| Global return | After 5 years |
| Lifetime sales | >3.25M units |
| Historical markets | >170 |
| Dakar record | 12 wins |
| Platform | Triton ladder frame |
| Drive control | S-AWC |
Lifetime Pajero sales equal 3.8 times Mitsubishi's current full-year volume target.
What the market still needs
AUG 24
Teaser updateReveal date and triple multi meter confirmed.
SEP 2
World premierePricing, powertrain and initial markets are key.
H2 FY26
Launch phaseManagement links Pajero to sales growth.
FY26
Plan test857,000 retail units and 2.8% margin.
Risk watch: procurement and shipping are a ¥28.7 billion headwind. Delays, discounting or costly launch inventory would press a narrow margin target.
Analyst expectations
2 Buy7 Hold3 Sell12-analyst poll, accessed August 26
Target range¥330–¥500
Average target¥372.83
52-week trading range¥300.70–¥458.00
Sources: Mitsubishi Motors official Pajero site and releases; Mitsubishi Motors Q1 presentation summary; StockAnalysis and Investing.com market and consensus data. Currency is Japanese yen. Estimates are explicitly marked.
PharmaceuticalsStock Market
Biohaven Shares Surge 25% Following Court’s $4 Million MODA Ruling
Shares of Biohaven jumped on Wednesday after a federal court finalized its win in a trade-secret lawsuit, boosting the clinical-stage drugmaker’s market capitalization by…
Biohaven • NYSE:BHVN
MODA Judgment: What the 25% Rally Prices
The cash award is small. Platform ownership and pivotal-stage optionality drove the read-through.
Market snapshot
August 26, 2026, 14:10 EDT
August 26, 2026, 14:10 EDT
Share price
$18.04
+$3.66 • +25.47%
Volume
10.34M
3.61× three-month average
Market value
$2.73B
About $553M added intraday
Analyst view
1.8
Yahoo classification: Buy
One-month price path
Intraday Aug. 26 price; earlier points use daily closes. The session high was $18.24.
Judgment math
The market-value response was about 138× the total award. Investors treated the judgment as platform validation, not income.
Financial frame
| Metric | Latest |
|---|---|
| Cash, securities and restricted cash | $270.5M |
| Q2 R&D expense | $100.8M |
| Q2 net loss | $137.3M |
| H1 operating cash use | $235.0M |
| Revenue | None |
Company guidance says existing resources fund at least one year. Further capital is still expected before meaningful product revenue.
Extracellular degrader milestones
Jun. 29
BHV-1300 Phase 3 began
Pivotal Graves’ disease trial enrolled its first patient.
Pivotal Graves’ disease trial enrolled its first patient.
2H 2026
BHV-1400 pivotal start
IgA nephropathy program targets registrational development.
IgA nephropathy program targets registrational development.
2H 2026
Other readouts
Obesity topline and epilepsy data remain separate valuation catalysts.
Obesity topline and epilepsy data remain separate valuation catalysts.
Evidence investors are underwriting
| Program | Target / disease | Reported signal | Stage |
|---|---|---|---|
| BHV-1300 | Pathogenic IgG / Graves’ | >80% mean antibody reduction at week 12 | Phase 3 |
| BHV-1400 | Gd-IgA1 / IgAN | ~70% reduction within first month | Pivotal start planned |
These are early biomarker findings. They do not establish clinical benefit or approval.
Risk watch
Legal: RA Capital has denied wrongdoing and signaled post-trial and appellate remedies plus patent counterclaims.
Clinical: The stock’s value depends on pivotal outcomes, safety, enrollment and regulatory review.
Financing: Pre-revenue cash use keeps dilution and debt terms material.
Sources: Biohaven releases dated Aug. 25 and Aug. 10, 2026; Biohaven Form 10-Q; Yahoo Finance market data; New Haven Register. Calculations use 151.04 million shares outstanding. Time-sensitive figures are stamped above.
Electric VehiclesSHA:600104
SAIC broadens India push as MG Hector Tomahawk EV launches from ₹1.95 million
India's family-SUV market gets two hybrid options with MG's Hector Tomahawk. The brand's battery-rental scheme further shifts car ownership costs towards a subscription model.
Product / commercial catalyst · SHA:600104
MG Hector Tomahawk: price, range and SAIC exposure
Product data: Aug. 26, 2026, 23:20 IST
SAIC close: Aug. 26, 2026, 15:00 CST
SAIC close: Aug. 26, 2026, 15:00 CST
EV price
₹1.95m
BaaS: ₹1.40m
EV range
517km
69.2kWh · 150kW
PHEV price
₹2.57m
BaaS: ₹2.18m
SAIC close
CN¥10.39
▲ 0.78%
Two electrified offers
| Metric | EV | PHEV |
|---|---|---|
| Battery | 69.2kWh | 20.5kWh |
| Electric range | 517km | 115km |
| Combined range | — | 1,100km+ |
| BaaS rental | ₹4.90/km | ₹3.20/km |
| Delivery start | September | November |
Upfront discount versus recurring cost
EV BaaS cuts entry cost 28.2%; PHEV BaaS cuts it 15.2%. At 10,000km per year, rentals add ₹49,000 and ₹32,000.
SAIC / India financial bridge
| JSW MG 2025 sales | 70,500 vehicles |
| Growth vs. 2024 | +15.6% |
| Current annual capacity | 120,000 |
| Planned annual capacity | 300,000 |
| Planned investment | $330m–$440m |
| FY2025 venture loss | $121m |
One percentage point of planned capacity equals 3,000 vehicles. Tomahawk needs sustained deliveries to raise utilization and dilute fixed costs.
SAIC market snapshot
| Close / daily move | CN¥10.39 / +0.78% |
| Volume | 32.57m shares |
| Market value | CN¥117.79bn |
| Trailing revenue | CN¥655.8bn |
| Trailing net income | CN¥10.11bn |
| Trailing P/E | 11.6× |
| Next earnings date | Aug. 29, 2026 |
What to watch
| Checkpoint | Timing | Signal |
|---|---|---|
| EV registrations | September | Search interest converting into paid deliveries |
| PHEV handovers | November | Demand for long-range hybrid packaging |
| Localization | 2026–2027 | Lower FX and freight exposure |
| Capacity ramp | Multi-year | Utilization against 300,000-unit target |
Bull case
- BaaS lowers the upfront barrier without eliminating lifetime revenue.
- ADAPT spreads engineering across EV and hybrid variants.
- India vehicle sales can grow into planned capacity.
Risks
Introductory prices cover limited volumes. Rentals may deter high-mileage drivers. Domestic rivals, charging gaps, continuing venture losses and India-China investment restrictions can slow returns.
Stock MarketTSX:L
Loblaw Resumes Tariff Labelling, Highlights C$15 Billion Retail Margin
Loblaw Companies Limited is reinstating tariff labels on store shelves as trade friction between Canada and the U.S. affects a wider range of products.…
Product / commercial catalyst · TSX:L
Loblaw’s tariff shelf labels meet a 32.2% retail margin
The returning “T” marker makes tariff exposure visible to shoppers. The investment question is whether sourcing changes keep merchandise costs inside Loblaw’s narrow quarterly margin range.
Market data: Aug. 26, 2026
12:34:48 EDT · CAD
12:34:48 EDT · CAD
Share price
C$61.26
+0.01% intraday
Range C$61.12–C$61.70
Market value
C$70.82bn
1.16bn shares outstanding
Valuation
25.93×
Trailing P/E · EPS C$2.36
Analyst view
C$71.00
15.9% implied upside
7 analysts · Moderate Buy
What changed
T
Loblaw will restore shelf markers for products whose prices are affected by tariffs. It will also restore country-of-origin labels in fresh produce.
Rollout begins with a small number of items and expands as tariffs reach more categories. Announced Aug. 26.
Latest operating base
| Q2 2026 | Result | YoY |
|---|---|---|
| Retail revenue | C$15.046bn | +4.1% |
| Food retail sales | — | +3.3% |
| Food same-store sales | — | +1.6% |
| Retail gross margin | 32.2% | +10 bp |
| Retail operating income | C$1.202bn | +2.9% |
| Retail free cash flow | C$856m | +C$235m |
Gross-profit sensitivity — not a forecast
A 10-basis-point shift equals about 1.25% of Q2 retail operating income. Actual tariff cost, pricing, mix and supplier mitigation are undisclosed.
Market read-through
| TSX ticker | Price | Day |
|---|---|---|
| Loblaw · L | C$61.26 | +0.01% |
| Metro · MRU | C$89.77 | −0.21% |
| George Weston · WN | C$98.07 | −0.27% |
The muted tape shows no broad grocery-sector repricing at the observation time.
Analyst expectations
Moderate Buy
| Strong buy | 1 |
| Buy | 4 |
| Hold | 2 |
| Average target | C$71.00 |
| Target vs. C$61.26 | +15.9% |
Consensus compilation dated Aug. 6, 2026.
What to watch next
Category reach: number and sales weight of products carrying the T marker.
Sourcing mix: domestic and non-U.S. substitutions against affected imports.
Margin: retail gross margin versus the latest 32.2% and +10-bp change.
Demand: food same-store sales and basket size after label expansion.
Risk line
Tariffs can raise procurement expense, but labels alone may not affect earnings. Domestic sourcing could offset costs; supplier shifts could also narrow assortment or add logistics expense. Without category-level exposure, the C$15.0 million sensitivity should not be read as a forecast.
Sources: Loblaw Q2 2026 release; The Canadian Press, Aug. 26; Google Finance market snapshot; MarketBeat analyst compilation. Financial figures in Canadian dollars.
![Asia Stock Market Today 27/08/2026 [UPDATE: 23:57 SGT] [Salesforce and Nvidia Lead KASE Global as Asia Closes Mixed]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-27-2355-1024x683.jpg "Asia Stock Market Today 27/08/2026 [UPDATE: 23:57 SGT] [Salesforce and Nvidia Lead KASE Global as Asia Closes Mixed]")
Stock Market
Asia Stock Market Today 27/08/2026 [UPDATE: 23:57 SGT] [Salesforce and Nvidia Lead KASE Global as Asia Closes Mixed]
Salesforce and Nvidia Lead KASE Global as Asia Closes Mixed27/08/2026 · 23:57 SGT LIVE SESSION · KASE GLOBAL Late Asia: software and chips lead…
BiotechnologyNASDAQ:RVMD
Rasonque FDA Approval Lifts Revolution Medicines Stock 0.8% at $45.7 Billion Valuation
Rasonque won U.S. approval Wednesday, giving Revolution Medicines, Inc. its first commercial product. The stock rose 0.77% to $213.01 at 11:55 a.m. EDT.
Rasonque approval dashboard
Revolution Medicines moves from trial risk to launch risk
NASDAQ:RVMD · PRODUCT/COMMERCIAL CATALYST
Market data: August 26, 2026
11:55 EDT / 17:55 Europe/Warsaw
11:55 EDT / 17:55 Europe/Warsaw
RVMD price
$213.01
+$1.63 · +0.77%
Market value
$45.65B
≈ $351M added today
Session range
8.3%
$198.91 low · $216.50 high
Volume by 11:55
1.10M
64% of 1.71M daily average
Session price map
Range positions are scaled from the verified session low and high. This is not a minute-by-minute price chart.
What changed
Rasonque is now a first-in-class, once-daily oral RAS inhibitor for certain adults with metastatic pancreatic cancer.
First product revenueNow possible
PricingNot disclosed
AvailabilityNot disclosed
Expanded-access patients2,000+
Phase 3 survival comparison
Rasonque median overall survival13.2 months
Standard chemotherapy6.7 months
Absolute improvement+6.5 months
Relative improvement+97%
Trial population500 adults
Valuation versus operating base
| Metric | Amount | Ratio to market cap |
|---|---|---|
| Quoted market value | $45.65B | 100% |
| Cash and securities, June 30 | $3.94B | 8.6% |
| 2026 operating-expense midpoint | $2.15B | 4.7% |
| Q2 operating expenses | $505.1M | 1.1% |
| Q2 net loss | $644.4M | 1.4% |
Cash equals 1.83× the midpoint of the current annual expense guide. It is not a formal runway estimate.
Analyst expectations
Buy ratings18
Hold ratings1
Average target$222.89
Implied upside4.6%
Target range$179–$291
Based on Google Finance’s 19-analyst, three-month set at the market-data timestamp.
What the valuation requires
Launch pricing and reimbursementNear term
Initial prescriptions and net salesNext reports
First-line pancreatic expansionPhase 3
RAS-mutant lung cancer readoutExpected 2027
Broad peak-sales estimate>$20B
The >$20B estimate assumes success beyond today’s approved patient group; current market value is about 2.3× that figure.
Catalyst timeline
Phase 3 survival data established the approval case.
Company reported U.S. launch readiness and $3.94B liquidity.
FDA approved Rasonque for the initial metastatic setting.
Pricing, availability, reimbursement and prescription uptake.
Risk monitor
Commercial
Pricing remains unknown. Slow coverage decisions can defer revenue even after approval.
Execution
Manufacturing limits or weak real-world uptake would pressure launch estimates.
Valuation
The average analyst target offers only 4.6% upside. Failed expansion trials would narrow the revenue base.
Investor bridge
Approval creates the first direct sales channel for Revolution Medicines. The financial test is whether Rasonque’s launch and later-label expansion can grow into a $45.65 billion valuation while annual operating expenses run near $2.15 billion.
NYSE:TGTStock Market
Target shares climb 0.6% as retailer rebounds from $25 costume controversy that wiped out $2.9 billion
MINNEAPOLIS, August 26, 2026, 11:48 – Target stock rose 0.6% on Wednesday following a rapid selloff that erased $2.9 billion in market value after…
NYSE:TGT · product-control catalyst
The $25 costume became a $2.9 billion valuation test
Market data: August 26, 2026
11:18–11:41 EDT
11:18–11:41 EDT
TGT intraday
$164.39
+$1.00 · +0.61%
Tuesday close
−3.78%
$169.89 → $163.47
Value erased
≈$2.92B
$6.42 × 454.19M shares
Consensus
$165.96
28 analysts · about 1% upside
Two-session price reset
The Wednesday bounce recovered only a small part of Tuesday’s product-governance repricing.
Catalyst anatomy
ProductKids’ clown costume
Ticket price$25
Private labelHyde & Eek! Boutique
Company actionRemoved + apologized
Investor channelBrand trust / traffic
merchandising controlsseasonal newnessOperating context
Q2 net sales$26.539B · +5.3%
Comparable sales+3.8%
Comparable traffic+3.6%
Digital comparable sales+8.7%
Operating margin9.6%
Margin ex tariff refund≈5.9%
Fastest core category
Fun 101 quarterly sales
$3.894B
+10.6% year over year · 14.7% of net sales
Q2 operating income$2.560B
Tariff refund benefit$994M
Underlying operating income≈$1.566B
Tuesday’s market-value loss equaled about 1.86× underlying quarterly operating income.
Peer and valuation snapshot
| Company | Price move | P/E | Avg target | Implied |
|---|---|---|---|---|
| Target | +0.61% | 17.0× | $165.96 | +1.0% |
| Walmart | −1.00% | 37.8× | $129.57 | +24.2% |
| Costco | −0.46% | 48.0× | $1,101.44 | +15.3% |
Google Finance, August 26, 2026. Analyst sample sizes: Target 28, Walmart 32, Costco 21.
What matters next
Upside checkTraffic stays positive
Core proofFun 101 retains growth
Process proofVisible review changes
Downside triggerBoycott pressure broadens
The direct merchandise loss is immaterial. Repeated failures would matter through traffic, conversion and markdown risk.